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Abstract 
Introduction 
Ductal carcinoma in situ (DCIS) accounts for approximately 10% of all newly-diagnosed breast cancers 
in the UK. The latest national guidelines were published in 2009 and may not reflect current best 
practice. We aimed to explore variation in the current management of DCIS to support the need for 
updated guidelines.     
Methods 
A national practice questionnaire was developed by the Mammary Fold Academic Committee (MFAC) 
focusing on the pre, intra and post-operative management of DCIS. Trainees at UK breast units were 
invited to complete the questionnaire at their multidisciplinary team meeting to provide a comprehensive 
picture of current national practice. 
Results 
76 of 144 UK breast units (52.8%) participated in the survey. Variation was observed in radiological 
pre-operative assessment with only 33/76 units (43.4%) performing routine ultrasound assessment of 
the tumour or axilla. There was no clear consensus regarding indications for mastectomy; multifocality 
(38.2%) and extensive microcalcifications (34.2%) were the most frequent indications. 34/76 units 
(44.7%) offered nipple sparing mastectomy. 33/76 units (43.3 %) perform sentinel node biopsy in the 
presence of a palpable/mass lesion and 51/76 (67.1 %) at the time of mastectomy. The most widely 
accepted pathological radial margin remained 2mm (36.8%). The commonest factors in decision-
making for radiotherapy were tumour grade (51.3%) and size (35.5%). Only 12 units (15.8 %) routinely 
used the Van Nuys prognostic index. Approximately half of all breast units offer clinical long-term follow-
up.   
Discussion 
There is marked variation in the management of DCIS in the UK.  Updated evidence-based guidelines 
may standardise practice and improve outcomes for patients. 
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Introduction 
Ductal carcinoma in situ (DCIS) is a pre-invasive breast cancer defined as the malignant clonal 
proliferation of cells within the basement membrane bound structures of the breast with no evidence of 
invasion[1].  A condition rarely diagnosed before the introduction of the national breast screening 
programme as the majority of lesions are impalpable[2], the age standardised incidence of DCIS has 
increased seven-fold from 3.3 per 100,000 in 1979 to 21.0 per 100,000 in 2012[3] due to the detection 
of lesions as microcalcifications on screening mammograms.  DCIS now represents 20% of all screen-
detected cancers and almost 13% of all new breast cancers in the UK with approximately 6400 new 
cases diagnosed in 2012 alone[3].    
Although thousands of women are diagnosed with DCIS each year, there is uncertainty regarding its 
optimal treatment as DCIS is a heterogeneous disease with variable malignant potential[4].  Evidence 
suggests that if left untreated, up to 35% of lesions may become invasive cancers within 10 years[5], 
however not all lesions will progress.  Data from the NHS Breast Screening Programme has failed to 
demonstrate any associated decrease in the incidence of invasive cancers that may have been 
expected with increased detection and treatment of pre-invasive disease[2].  This has led to concerns 
regarding both ‘overdiagnosis’ and ‘overtreatment’ particularly for low grade lesions.  The benefits of 
diagnosis and treatment of DCIS, however, were recently identified in a study suggesting a decrease 
in the rate of interval cancers in this group[6].   
In the absence of data to definitively support a conservative approach, surgery aiming to excise the 
primary lesion and prevent recurrence remains the mainstay of treatment for DCIS.  This is important, 
as although DCIS has low metastatic potential, up to 50% of all recurrences will be invasive disease[7] 
with the associated risk of metastases and death.  Local recurrence rates may be as high as 8% 
following mastectomy and 21.5% following breast conserving surgery alone[7]. Recent Cochrane 
reviews have highlighted reductions in local recurrence rates with adjuvant radiotherapy[8] and also 
with adjuvant tamoxifen[9] in women with ER positive disease managed with breast conservation. 
Effective evidence-based guidelines for the management for DCIS are therefore vital if outcomes for 
patients are to be improved.  Both the National Institute of Health and Care Excellence (NICE)[10] and 
the Association of Breast Surgery (ABS) at the British Association of Surgical Oncology (BASO)[11] 
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have produced guidelines for the management of breast cancer which include recommendations for the 
management of DCIS (table 1).  However, there are no guidelines specific to the condition and both 
these publications date from 2009.  They therefore do not reflect new evidence regarding the optimal 
management of DCIS, the development of new surgical techniques such as therapeutic mammoplasty 
or new prognostic technologies such as Oncotype DX DCIS[12] and may therefore not reflect best 
practice. 
The aim of this study was therefore to explore variations in national practice regarding the management 
of pure DCIS to support the need for new evidence-based guidelines to standardise practice and 
improve outcomes for women diagnosed with the condition in the future. 
Methods 
The Mammary Fold is the UK national breast trainees association. A national practice questionnaire 
was developed by members of the Mammary Fold Academic Committee (MFAC) with expert 
multidisciplinary input from surgeons (Mr Stewart Nicholson), pathologists (Professor Andrew Hanby) 
and oncologists (Professor David Dodwell) involved in the Sloane Project, a UK wide prospective audit 
of the management and long term outcomes of screen-detected in situ carcinoma and atypical 
hyperplasia of the breast[13-16].  The survey covered all aspects of the management of DCIS including 
pre-operative assessment and decision-making; intra-operative management and post-operative 
pathological assessments; decision-making for adjuvant therapy, and follow-up.  The survey was piloted 
by committee members at local units to ensure completeness and determine face and content validity 
of the survey prior to study initiation. 
Trainee research collaboratives[17] consisting of surgical trainees at different units working together to 
design and deliver of high-quality research[18] and audit[19, 20] are well-established in general surgery 
and increasingly in sub-specialities such as breast surgery[21]. Trainees working at breast units across 
the UK were invited to participate in the study via the Mammary Fold and local deaneries.  All trainees 
were medically-qualified doctors in general surgical training.  Participants were asked to complete the 
survey at their unit’s multidisciplinary team meeting (MDT) to ensure the responses reflected practice 
in the unit as a whole rather than the views of individual practitioners.   
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Study data were collected and managed using REDCap electronic data capture tools hosted at 
University of Edinburgh[22].  REDCap (Research Electronic Data Capture) is a secure, web-based 
application designed to support data capture for research studies, providing 1) an intuitive interface for 
validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated 
export procedures for seamless data downloads to common statistical packages; and 4) procedures for 
importing data from external sources.    
Simple summary statistics were calculated for each survey item to evaluate variations in pre, intra and 
post-operative assessment and treatment.  Appropriate non-parametric statistics were used to explore 
variables that may influence practice.  STATA V13.1 (www.stata.com) was used for all analyses. 
Results 
A total of 133 records were entered onto the REDCap database.  Of these, 15 lacked identifiable unit 
name and were excluded from the analysis.  Of the remaining 118 records, 42 were identified as partially 
completed duplicates and excluded.  A total of 76 units therefore contributed data to the study of which 
52 units entered complete data sets. 
Unit demographics 
Of the 76 participating units, 66 (86.8%) treated both symptomatic patients and those referred from 
NHS Breast Screening Programme while 9 (11.8%) managed symptomatic patients only.  Units treated 
a median of 200 new invasive symptomatic cancers per year (inter-quartile range 143-336) with no 
difference in case volume between screening and symptomatic units (table 2).        
Unit guidelines for the management of DCIS 
A total of 47/76 units reported having written guidelines for the management of DCIS.  These were most 
commonly combined with those for invasive disease (n=44) with only three reporting stand-alone 
guidance for pre-invasive lesions (table 2).   
Pre-operative imaging 
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Pre-operative assessment varied widely between units.  Ultrasound was used routinely for planning 
surgery in 33/76 units, but five units did not routinely scan patients pre-operatively and a further 16 did 
so only in selected cases, most commonly when the lesion was palpable (n=8).  
In line with NICE guidance[10], MRI was not routinely used in pre-operative planning for DCIS and over 
a third of units (n=27) reported that they never used this imaging modality in patients with pre-invasive 
disease.  A number of units (n=27) reported using MRI in specific circumstances including when there 
is uncertainty about the extent of the DCIS (n=5); mammographically occult lesions (n=5); size 
discrepancies between imaging modalities (n=4) or if invasive foci were anticipated in high-grade (n=2) 
or large lesions (n=3).    
The axilla was routinely imaged by USS in almost half of responding units (n=33) with only 3 units 
reporting that the axilla was never imaged pre-operatively in DCIS patients.  A further 15 units imaged 
the axilla selectively.  Indications for axillary imaging in these units included the presence of a palpable 
mass (n=6), other features that may predict invasion (n=18), or if a mastectomy was planned (n=3). 
Pre-operative pathological diagnosis 
Core biopsy was the first line for establishing a diagnosis of DCIS in many of the units surveyed (n=17).  
The use and availability of vacuum-assisted biopsy (VAB) was much more restricted with only 8 units 
reporting that it was first line for the diagnosis of microcalcifications.  VAB was not available in seven 
units and available but not used in a further 11.  Eight units used VAB in selected cases including small 
lesions and lesions in which the diagnosis was difficult.   
Indications for mastectomy 
To reduce the risk of recurrence, the ABS at BASO guidelines recommend patients with ‘extensive’ 
(greater than 40mm) or multicentric disease should usually undergo a mastectomy[11].   Multifocality 
was considered an indication for mastectomy by many units (n=29), but size criteria were less 
consistently applied.  Eleven units used 40mm as an indication for mastectomy but seven units reported 
offering breast conservation for up to 50mm of DCIS.  A further 13 units reported that they considered 
the size of the lesion in relation to the size of the breast rather than applying an absolute size criterion 
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when considering whether breast conservation was feasible.   A quarter of units (n=19) reported having 
no specific indications for mastectomy and assessed patients on a case by case basis (table 2). 
Breast reconstruction was offered to women requiring mastectomy by the majority of units (57/76) with 
34/76 units offering women the possibility of nipple sparing procedures if the lesion was away from the 
nipple-areolar complex (n=9) or a subareolar biopsy was clear of disease (n=6).  Therapeutic 
mammoplasty was also widely offered (n=49).   
Sentinel node biopsy 
Current guidelines recommend performing a sentinel lymph node biopsy (SLNB) in patients at high risk 
of invasive disease or those undergoing mastectomy[11].  Although the majority of units (n=51/76) 
reported undertaking SLNB when mastectomy was performed, there was a lack of consistency 
regarding other indications.  Those reported were variable but included performing SLNB for mass-
forming/palpable (n=33); high-grade (n=8) or multifocal (n=6) lesions (table 2).   
Intra-operative assessment of excision specimens 
The ABS at BASO guidelines[11] recommend that intra-operative specimen radiography should be 
performed in all cases of DCIS treated with breast conserving surgery (BCS).  Only 27 units, however, 
routinely imaged their excision specimens intra-operatively.  Twenty-three units used specimen 
radiography for wire-guided excisions only.  One unit reported that intraoperative imaging was not 
available and a further unit reported that it was never performed.  Portable imaging devices and 
departmental imaging were used with equal frequency (table 2).   
For those patients undergoing SLNB, One Step Nucleic Acid Amplification (OSNA) was used routinely 
in DCIS in seven units, but was not available in the majority of the remainder (n=42).  
Pathological assessment 
NICE guidance recommends a minimum of a 2mm excision margin in patients with DCIS to reduce the 
risk of local recurrence[10].  Twenty-eight units followed this guidance, but there was a lack of 
consensus regarding what was considered an acceptable margin.  Following the recent ABS consensus 
process, 17 units reported using a 1mm margin and a further six units used ‘no tumour on ink’ consistent 
Variation in the management of DCIS in the UK 
8 
 
with the SSO (Society of Surgical Oncology)/ASTRO (American Society for Radiation Oncology) 
guidelines for invasive disease[23].  One unit reported that 5mm was the minimum acceptable margin 
and a further unit reported that margin width depended on the grade of disease with a 10mm margin 
required for high-grade DCIS.   
Routine receptor status testing in DCIS was very variably applied.  Oestrogen receptor status was 
routinely assessed by 22 units; progesterone receptor status by 17 units and HER-2 status by only 
eight.  Where receptor status was determined, this was predominantly on the core biopsy specimen 
(n=15) with a minority using tissue from the excision specimen itself (n=3).  Seven units assessed 
receptor status on both the biopsy and excision specimens. 
In terms of risk stratification, the Van Nuys Prognostic Index was only used routinely by 12 units.  A 
further five units used it in certain circumstances such as when considering radiotherapy or for high 
grade disease.  The newly developed Oncotype DX DCIS recurrence score was only used routinely by 
one unit and was not available in the remainder. 
Adjuvant therapy 
Although NICE guidelines recommend against offering patients with DCIS endocrine therapy[10], six 
units routinely did so and a further 12 offered treatment to patients considered to be a high risk of 
recurrence such as young patients with high-grade disease. 
The offer of radiotherapy (RT), including a discussion of the risks and benefits of treatment, is currently 
recommended for all women having BCS for DCIS[10].  Although ten units routinely offer RT on this 
basis, other units offer RT to selected patients only.  A lack of consensus was demonstrated regarding 
the indications for treatment with tumour grade (n=39), size (n=27), patient age (n=23), presence of 
comedo necrosis (n=21) and margin width most frequently influencing recommendations for RT.  The 
Van Nuys Prognostic Index was used infrequently in decision making (n=10) and when it was 
calculated, there was a lack of consistency with regard to the scores that would determine whether RT 
would be beneficial (table 2).  
Follow-up 
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There was similar variability in the way patients with DCIS were followed up across the UK.  Thirty-
seven units reviewed patients in clinic annually, often for five years (n=26) while 20 units offered women 
open access appointments for variable periods of time (five years (n=13) to life-long access (n=3)).  
Mammographic follow up was offered by 52 units, most commonly on an annual basis for between 5 
and 10 years as recommended in the NICE guidelines[10].   
Audit 
Although NICE recommend that all breast units should audit their local recurrence rates[10], only 17 
units prospectively audited their results.  Of these, five entered patients into national studies such as 
BCCOM, Sloane and ‘Forget Me Not’ with the remainder auditing their results locally (table 2). 
Discussion 
This study demonstrates marked variation in the management of pure DCIS across breast units in the 
UK.  There is a lack of consistency with regard to pre-operative planning; intra-operative practice and 
post-operative management.  Indications for mastectomy varied dramatically between units and there 
was no consistent indication for SLNB at the time of surgery.  Despite the recent ABS consensus on 
margins, few units used 1mm as acceptable pathological margin with the majority retaining the original 
2mm margin recommended in the 2009 NICE guidelines[10].  Receptor status was not routinely 
assessed in the majority of centres and endocrine therapy was rarely used.  Radiotherapy was also 
offered variably with no consistent indications demonstrated.  Follow up was variable and few units 
routinely audited their results.   
Variation in the management of DCIS has been previously been demonstrated from both a national[13, 
15, 16, 24] and international[25, 26] perspective.  Data from the Sloane Project, a multicentre UK wide 
audit of screen-detected DCIS has demonstrated variation in both the mastectomy rate[15] and the 
axillary management[16] in women with DCIS and a lack of consensus regarding the duration and 
frequency of follow-up in these patients[13].   Similarly, data from 12 countries and 15 screening 
programmes within the International Cancer Screening Network (ICSN) suggested marked variation in 
BCS rates ranging from 67-90% with radiotherapy following BCS given in between 41 and 100% of 
cases.  Axillary management was similarly variable with 5% of women undergoing BCS and 20% of 
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those undergoing mastectomy receiving axillary dissection[25] although this practice was not supported 
by any national guidelines.               
One explanation for the lack of adherence to guidelines in the current study may be that as they were 
published in 2009, UK guidelines[10, 11] are now outdated and do not reflect evidence-based best 
practice.  Updating these or promoting adoption of the National Comprehensive Cancer Network 
(NCCN) guidelines (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#breast) which 
are updated annually may be therefore one way in which variation in the management of DCIS may be 
addressed.  There is, however, currently controversy regarding the optimal management of this 
heterogeneous disease and the lack of consensus regarding best practice may be equally responsible 
for the variability seen.  Overtreatment, particularly for low grade screen-detected lesions, is an 
increasing concern and the LORIS (Low Risk DCIS) trial is currently randomising women with low and 
intermediate grade DCIS to surgery or active monitoring to address this important question[27].  A more 
targeted approach to the use of adjuvant therapies following breast conservation for DCIS is also likely 
to be necessary if women are to receive optimal care.  The adoption of molecular phenotyping using 
ER, HER-2 and Ki67 status[28] or commercially available techniques such as the recently validated 
Oncotype DX DCIS[29] may help effectively stratify patients and identify those at higher risk of 
recurrence who may benefit from the addition of adjuvant therapies and those who may be effectively 
managed by local excision alone.  The management of DCIS is an evolving field; identifying areas of 
uncertainty, developing trials to address these and encouraging clinicians to recruit their patients into 
new and on-going studies will therefore be necessary if the current controversies are to be addressed 
and the care for patients improved   
This study has demonstrated previously significant variability in the current management of DCIS across 
the UK.  This is an important finding, but some aspects of the work require further consideration.  Firstly, 
the results are based on survey data and it may be that actual practice in the individual units differs 
from the responses provided.  There may also be response bias with participating units differing 
significantly from those that were not involved.  The broad variability and general lack of adherence to 
current guidance observed, however, suggests that this is unlikely.  Furthermore, the questionnaires 
were completed at unit multidisciplinary meetings which makes significant deviation between reported 
and actual practice doubtful.  Concern may be raised, however, regarding the proportion of 
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‘missing/unknown’ responses which ranged from 1-33% across items in the study.  Using the MDT 
approach should have made the data more robust, but if there was disagreement between MDT 
participants, the trainee, as a junior member of the team, may not have felt empowered to request a 
definitive response, question senior colleagues or know where to find additional data such as number 
of cases, if these were not available at the meeting.  This could explain why the missing data rates were 
comparatively high.  Although 76 units contributed to the study, only 52 provided complete data sets.  
The responses presented therefore only represent between 36 and 53% of the 144 breast units in the 
UK.  This study was conducted as a trainee-led collaborative project and unit participation was 
dependant on a motivated trainee engaging the MDT.  Not all UK breast units have a trainee and the 
project may have benefited from a ‘dual prong’ approach to engage consultants through the professional 
associations as well as trainees in order to optimise participation.  Using the trainee model may, 
however, have unintentionally introduced bias into the study as larger units with higher case volume 
would be more likely to host trainees and therefore may have been more likely to participate than 
smaller, lower volume centres which may have practiced differently.  Collaborative research, however, 
is a relatively new concept in breast surgery and the best strategy for optimising the potential of this 
methodology is still being explored.  Establishing a strong and reliable research network will be 
necessary for completion of future projects.  Finally, there was a significant ‘drop-out’ rate in the study 
with over 30% of participants starting, but not completing the survey.  This may reflect the complexity 
and length of the questionnaire and inclusion of data items regarding the unit’s activity, which may not 
have been immediately available at the point of completion.  This was not identified during the piloting 
phase, but would be an important learning point for future studies.  Although less than anticipated, 
however, results from over a third of UK breast units provides an insight into national practice and the 
need to standardise the management of this important condition.          
This study has demonstrated marked variability in the management of pure DCIS.  Updating existing 
guidelines to reflect best practice and promoting active participation in research and audit to address 
areas of uncertainty may be one way in which this variability may be addressed.  Developing these 
guidelines and identifying the areas where new research is needed will be the next important step in 
this process.  Involvement and engagement of trainees in collaboration with multidisciplinary experts 
may be a novel means by which this guidance and new trial ideas may be developed.  Trainee research 
collaboratives are integral to the Royal College of Surgeons Surgical Trials Initiative[30] and have an 
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excellent track record in the design and delivery of well-designed prospective cohort studies[19-21, 31, 
32] and randomised clinical trials[18], but have yet to be involved in generating best-practice guidelines.  
Developing new guidelines for the management of DCIS based on the results of this study may provide 
trainees with an exciting opportunity to shape practice and impact on care for patients across the UK. 
Trainees could also play a valuable role in the design and delivery of future DCIS studies, siting on 
steering groups and learning about trial methodology in a practical way.  Educating and empowering 
trainees in individual units to recruit to new and ongoing DCIS trials may also be a useful way in which 
they may contribute to improving patient care.  Furthermore, involving trainees at an early stage in their 
careers so they understand the need for RCTs may generate research capacity by creating a new 
generation of research active consultant surgeons who will engage in and recruit to trials to improve the 
future care of women with breast cancer. 
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Table 1 – Summary of UK Guidelines relating to the management of ductal carcinoma in situ (DCIS) 
 
Referral, diagnosis and preoperative assessment of patients with DCIS 
The routine use of MRI of the breast is not recommended in the preoperative assessment of patients with biopsy-proven DCIS  NICE CG80 
Patients with DCIS should be fully informed of the surgical treatment options available to them - When appropriate, patients should be given 
an informed choice between BCS and mastectomy. This includes the difference in local recurrence rates between the two approaches. If a 
choice of breast conservation surgery is not offered the reasons should be documented in the patient’s case notes 
ABS at BASO 
Patients with DCIS should have access to BCS - All patients having treatment by mastectomy (by choice or on advice) should have the 
opportunity to discuss their breast reconstruction options and have immediate breast reconstruction if appropriate. If breast reconstruction is 
not offered the reasons should be documented in the patient’s case notes 
ABS at BASO 
To minimise local recurrence after BCS for DCIS - Patients with extensive (>40 mm diameter) or multi-centric disease should usually undergo 
treatment by mastectomy 
ABS at BASO 
Surgical management of DCIS 
Intra-operative specimen radiography should be carried out for all cases of DCIS treated by BCS ABS at BASO 
For all patients treated with BCS for DCIS a minimum of 2 mm radial margin of excision is recommended with pathological examination to 
NHSBSP reporting standards. Re-excision should be considered if the margin is less than 2 mm, after discussion of the risks and benefits 
with the patient. 
NICE CG80 
All patients should have their tumours removed with no evidence of disease at the microscopic radial margins and fulfilling the requirements 
of local guidelines If, after MDT meeting discussion, the margin of excision is deemed to be inadequate then further surgery to obtain clear 
margins should be recommended 
ABS at BASO 
Axillary staging surgery is not routinely recommended for patients having treatment for DCIS alone. It may be considered in patients 
considered to be at high risk of occult invasive disease. The decision to carry out an axillary staging procedure should be discussed at the 
pre-operative MDT meeting and recorded in the patient’s case notes. 
ABS at BASO 
Do not perform SLNB routinely in patients with a preoperative diagnosis of DCIS who are having BCS, unless they are considered to be at a 
high risk of invasive disease (high risk of invasive disease includes those with a palpable mass or extensive microcalcifications) 
NICE CG80 
Offer SLNB to all patients who are having a mastectomy for DCIS NICE CG80 
Variation in the management of DCIS in the UK 
18 
 
Post-operative adjuvant therapy in DCIS 
Do not offer adjuvant tamoxifen after breast conserving surgery to patients with DCIS NICE CG80 
Offer adjuvant radiotherapy to patients with DCIS following adequate BCS and discuss with them the potential benefits and risks NICE CG80 
Follow-up in DCIS  
Offer annual mammography to all patients with early breast cancer, including DCIS, until they enter the NHSBSP/BTWSP. Patients 
diagnosed with early breast cancer who are already eligible for screening should have annual mammography for 5 years 
NICE CG80 
Do not offer ultrasound or MRI for routine post-treatment surveillance  NICE CG80 
Audit and quality control  
Enter patients with screen-detected DCIS into the Sloane Project (UK DCIS audit) NICE/ABS 
All breast units should audit their recurrence rates after treatment for DCIS  
(<10% BCS for DCIS should develop local recurrence at 5 years (ABS at BASO standard) 
NICE CG80 
ABS – Association of Breast Surgery; BASO – British Association of Surgical Oncology; BCS – breast conserving surgery; BTWSP – Breast Test Wales Screening 
Programme; MRI – magnetic resonance imaging; NHSBSP – National Health Service Breast Screening Programme; NICE – National Institute of Health and Care Excellence; 
SLNB – sentinel lymph node biopsy 
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Table 2 – Summary of DCIS survey data 
Breast unit demographics  N=76 (%) 
Unit type 
Symptomatic only 
Screening and symptomatic 
Missing 
 
9 (11.8) 
66 (86.8) 
1 (1.3) 
Unit volumes (median, IQR) 
Symptomatic invasive (n=42) 
Symptomatic non-invasive (n=37) 
Screen-detected invasive (n=37) 
Screen-detected non-invasive (n=35) 
 
200 (143-336) 
20 (10-40) 
90 (45-134) 
25 (14-50) 
Availability of breast reconstruction  
Yes, in same Trust 
Yes, in same hospital 
Yes, at another hospital Trust 
Not offered 
Don’t know/Missing 
 
25 (32.9) 
29 (38.2) 
3 (3.9) 
0 (0.0) 
19 (25.0) 
Pre-operative assessment and planning  
Written guidelines for DCIS 
As part of breast cancer guidelines 
Separate guideline 
No guidelines 
Don’t know/Missing 
 
44 (57.9) 
3 (3.9) 
7 (9.2) 
22 (28.9) 
Use of pre-operative USS for surgical planning for DCIS 
Not used 
Used routinely  
Used in selected cases 
Don’t know/Missing 
 
5 (6.6) 
33 (43.4) 
16 (21.1) 
22 (28.9) 
Use of pre-operative MRI for surgical planning for DCIS 
Not used 
Used routinely  
Used in selected cases 
Don’t know/Missing 
 
27 (36.5) 
0 (0.0) 
27 (36.5) 
22 (28.9) 
Use of vacuum assisted biopsy for DCIS 
First line for microcalcifications 
Second-line after core biopsy 
Not available 
Available but not routinely used 
In selected cases 
 
8 (10.5) 
17 (22.4) 
7 (9.2) 
11 (14.5) 
8 (10.5) 
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Don’t know/Missing 25 (32.9) 
Indications for mastectomy 
>40mm DCIS on imaging 
>50mm DCIS on imaging 
Multifocal  
‘Extensive’ microcalcification on mammography 
No specific indications 
 
11 (14.5) 
7 (9.2) 
29 (38.2) 
26 (34.2) 
19 (25.0) 
Nipple sparing mastectomy offered 
Yes 
No 
Don’t know/missing 
 
34 (44.7) 
19 (25.0) 
23 (30.3) 
Therapeutic mammoplasty offered 
Yes 
No 
Don’t know/missing 
 
49 (64.5) 
4 (5.3) 
23 (30.3) 
Pre-operative imaging of axilla in DCIS 
Routinely performed 
Never performed 
Performed in certain circumstances 
Don’t know/missing 
 
33 (43.4) 
3 (3.9) 
15 (19.7) 
25 (32.9) 
Indications for sentinel node biopsy in DCIS 
Performed in all cases 
For palpable/mass lesions 
For multifocal DCIS 
When performing a mastectomy 
For high grade DCIS 
For extensive microcalcification 
 
0 (0.0) 
33 (43.4) 
6 (7.9) 
51 (67.1) 
8 (10.5) 
4 (5.7) 
Timing of SNB when immediate reconstruction planned 
Before reconstruction (stand-alone SNB) 
At time of reconstruction 
Don’t know/missing 
 
17 (22.4) 
31 (40.8) 
28 (36.8) 
Intra-operative assessment  
Use of intra-operative specimen radiography  
For all lesions treated by wide local excision 
For lesions requiring radiological localisation only 
Not routinely available 
Not performed 
Don’t know/missing 
 
27 (36.5) 
23 (30.3) 
1 (1.3) 
1 (1.3) 
24 (31.6) 
Type of specimen radiography 
Departmental XR 
 
25 (32.9) 
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Portable device e.g. Faxitron 
Not applicable 
Don’t know/missing 
27 (36.5) 
1 (1.3) 
23 (30.3) 
Use of OSNA in DCIS 
Used routinely 
For invasive lesions only 
OSNA not available 
Don’t know/missing 
 
7 (9.2) 
4 (5.3) 
42 (55.3) 
23 (30.3) 
Pathological assessment  
Acceptable radial margin 
No ink on margin 
1mm 
2mm 
5mm 
Dependant on grade of DCIS (10mm for HG-DCIS) 
Don’t know/missing 
 
5 (6.6) 
17 (22.4) 
28 (36.8) 
1 (1.3) 
1 (1.3) 
24 (31.6) 
Routine ER receptor testing on DCIS 
Yes 
No 
Don’t know/missing 
 
22 (28.9) 
30 (39.5) 
24 (31.6) 
Routine PR receptor testing on DCIS 
Yes 
No 
Don’t know/missing 
 
17 (22.4) 
35 (46.1) 
24 (31.6) 
Routine HER-2 receptor testing on DCIS 
Yes 
No 
Don’t know/missing 
 
8 (10.5) 
43 (56.6) 
25 (32.9) 
Specimen used for assessing receptor status (n=25) 
Core biopsy 
Pathological specimen 
Both 
 
15 (60.0) 
3 (12.0) 
7 (28.0) 
Use of Van Nuys Prognostic Index in patients with DCIS 
Routinely used 
Not used 
Used in certain circumstances 
Don’t know/missing 
 
12 (15.8) 
36 (47.4) 
5 (6.6) 
23 (30.3) 
Use of Oncotype DX DCIS recurrence score 
Routinely used 
Not used 
 
1 (1.3) 
51 (67.1) 
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Used in certain circumstances 
Don’t know/missing 
1 (1.3) 
23 (30.3) 
Use of SNB if micro-invasion detected on resection 
specimen, if SNB not originally performed 
Yes 
No 
In certain circumstances 
Don’t know/missing 
 
 
32 (42.1) 
7 (9.2) 
12 (15.8) 
25 (32.9) 
Treatment of patients with DCIS  
Use of endocrine therapy in patients who are ER +ve 
Yes 
No 
In certain circumstances 
Don’t know/missing 
 
6 (7.9) 
34 (44.7) 
12 (15.8) 
24 (31.6) 
Factors considered when recommending radiotherapy to 
patients treated with breast conserving surgery 
All women offered RT 
Van Nuys Prognostic Index only 
Tumour size 
Presence of comedo necrosis 
Margin width 
Patient age 
Tumour grade 
Multifocality 
Other 
 
 
10 (13.2) 
10 (13.2) 
27 (35.5) 
21 (27.6) 
20 (26.3) 
23 (30.3) 
39 (51.3) 
16 (21.1) 
7 (9.2) 
Van Nuys cut off for recommending RT Range 3-10 
Follow up of patients with DCIS  
Follow up of patients after treatment for DCIS 
Breast clinic follow-up with clinical review annually 
For 1 year 
For 2 years 
For 3 years 
For 5 years 
Other  
Open access clinic 
For 5 years 
For 10 years 
Lifelong 
As requested by GP 
Mammographic follow up 
 
37 (48.7) 
3 
2 
2 
26 
2 
20 (26.3) 
13 
1 
3 
1 
52 (68.4) 
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For 5 years 
For 10 years 
Other  
Mammographic frequency 
Annual 
Every 2 years 
39 
10 
7 
 
48 
2 
Audit  
Prospective audit of treatment of patients with DCIS 
Yes 
No 
Details 
National audit (BCCOM, Sloane, Forget me not etc) 
Local audit 
 
15 (19.7) 
38 (50.0)  
 
5 (33.3) 
9 (60.0) 
 
 
 
